These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16918105)

  • 1. The evolving role of exemestane in the management of breast cancer.
    Bundred N
    Br J Hosp Med (Lond); 2006 Aug; 67(8):427-30. PubMed ID: 16918105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 3. Exemestane: an alternative treatment option in early breast cancer. Foreward.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S1. PubMed ID: 18340241
    [No Abstract]   [Full Text] [Related]  

  • 4. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
    Goss PE; Richardson H; Chlebowski R; Johnston D; Sarto GE; Maunsell E; Ingle JN; Alés-Martinez JE
    Clin Breast Cancer; 2007 Dec; 7(11):895-900. PubMed ID: 18269782
    [No Abstract]   [Full Text] [Related]  

  • 7. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intergroup Exemestane Study mature analysis: overall survival data.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane: a milestone against breast cancer.
    Shetty YC; Chakkarwar PN; Acharya SS; Rajadhyaksha VD
    J Postgrad Med; 2007; 53(2):135-8. PubMed ID: 17495383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exemestane or tamoxifen?
    Atkins CD
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
    [No Abstract]   [Full Text] [Related]  

  • 12. Update: a 62-year-old woman with a new diagnosis of breast cancer.
    Farag N; Burns R; Come SE
    JAMA; 2008 Mar; 299(9):1055-6. PubMed ID: 18319415
    [No Abstract]   [Full Text] [Related]  

  • 13. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
    Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
    Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
    Lundkvist J; Wilking N; Holmberg S; Jönsson L
    Breast Cancer Res Treat; 2007 May; 102(3):289-99. PubMed ID: 17033927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
    Risebrough NA; Verma S; Trudeau M; Mittmann N
    Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical analysis in cancer clinical trials.
    Jeong JH
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S9-10. PubMed ID: 18340243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitors for therapy of advanced breast cancer.
    Ingle JN; Suman VJ
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):113-9. PubMed ID: 15939585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.